ERBB2 and gastric carcinoma: There is extensive experience in HER2 testing for breast and gastric carcinomas, in contrast to a notable lack of a standardized method for HER2 evaluation in EC, a critical step for precise patient triage and optimizing the selection of patients who may benefit from HER2-targeted therapy with monoclonal antibodies and, possibly, with antibody drug conjugates.